Over the past few years a number of Canadian provinces have amended or revised their legislation furthering the scope of practice for health professionals in order to accommodate the growing demands for patient care on the healthcare system. The expanded scope of practice specific to Nurse Practitioners has the potential to significantly impact prescribing and ultimately the ways in which pharmaceutical manufacturers communicate and market their products.
Whereas traditional pharmaceutical marketing in Canada has primarily targeted the physician as being the only ‘authorized prescriber’, recent changes to national and provincial legislations has altered the playing field with the resultant emergence of a new authorized prescribing group.
This MD Analytics’ Nurse Practitioner Prescribing report provides an in-depth province-by-province review of the expanded practice scope of Nurse Practitioners. Building on the key findings from this expanded report, first published in 2009; it will also include tracking on key awareness and usage trends to further analyze potential impact and rate of uptake.
With this study you will acquire a detailed understanding of the evolving prescribing authorization amongst Nurse Practitioners. Gain a better understanding where the opportunities are to initiate new prescriptions. As well as, learn how to develop finely tuned communication strategies by province and therapeutic categories to grow and protect your scripts.